Drug Profile
Pranoprofen
Alternative Names: Difen Oculum; difen oculum; Niflan; Niflan Ophthalmic Solution; Oftalar; Pranopulin Ophthalmic Solution; Pranox; SJH 1012; Y 8004Latest Information Update: 18 May 2020
Price :
$50
*
At a glance
- Originator Mitsubishi Pharma Corporation
- Developer AbbVie; Alcon Cusi; Mitsubishi Tanabe Pharma Corporation; Senju Pharmaceutical; Takeda
- Class Benzopyrans; Nonsteroidal anti-inflammatories; Propionic acids
- Mechanism of Action Cyclooxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Fever; Inflammation; Ocular inflammation; Pain
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 01 Oct 2007 Mitsubishi Pharma Corporation has merged with Tanabe Seiyaku to form Mitsubishi Tanabe Pharma Corporation
- 06 Apr 2000 Yoshitomi is now called Welfide Corporation